Verdict No. 3048 · Search date 2026-09-08 · Methodology v1.0
Aphios purified liquid ginger-extract capsules as add-on therapy,
does it really help with Reduction of acute nausea severity in the first 24 hours after chemotherapy?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Only acute-nausea severity in the first 24 hours is judged; delayed nausea, vomiting, and quality of life are separate.
Caution. Ginger is not a replacement for antiemetics during cancer care. Gastrointestinal effects and possible anticoagulant or antiplatelet interactions should be reviewed with the oncology team.
What the
research showsGrade C with 50 points. In a multicenter trial with 744 randomized and 576 analyzed, adding ginger extract to standard antiemetics produced an adjusted day-one mean-nausea change difference of -0.350 points (P=.013). The paper and current registry disagree on the primary endpoint, and an exact 95% CI and same-formulation replication are unavailable.
research showsGrade C with 50 points. In a multicenter trial with 744 randomized and 576 analyzed, adding ginger extract to standard antiemetics produced an adjusted day-one mean-nausea change difference of -0.350 points (P=.013). The paper and current registry disagree on the primary endpoint, and an exact 95% CI and same-formulation replication are unavailable.
What the
ads claimGinger cannot replace standard antiemetics, and delayed nausea, vomiting, or quality-of-life results cannot be recast as acute-nausea success.
ads claimGinger cannot replace standard antiemetics, and delayed nausea, vomiting, or quality-of-life results cannot be recast as acute-nausea success.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Ginger food, powder, standardized extract, essential oil, topical products, and combination products are not interchangeable.
- Caution. Ginger is not a replacement for antiemetics during cancer care. Gastrointestinal effects and possible anticoagulant or antiplatelet interactions should be reviewed with the oncology team.
Chamgap Semantic Classification Code
Permanent code issued
S.ginger.oral-addon.acute-chemotherapy-nausea-severity.reduce.addonSupplements and nutraceuticals > Ginger > Oral add-on > Acute chemotherapy nausea severity > Reduction claim > Add-on to standard antiemetics
Bound to nausea severity in the first 24 hours; delayed nausea and vomiting remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Ginger |
| Source or part used | Rhizome of Zingiber officinale Roscoe |
| Formulation or processing | Aphios purified liquid ginger extract in olive-oil carrier capsules |
| Route | Oral add-on |
| Dose | 250-mg root-equivalent per active capsule; 0.5, 1, or 1.5 g/day equivalents twice daily |
| Duration | Six days in each of two cycles, starting three days before chemotherapy |
| Population | Adults with prior chemotherapy nausea on a 5-HT3 antagonist plus corticosteroid |
| Effect or condition | Acute-nausea severity reduction |
| Primary endpoint | Change in mean evening/night day-one nausea on a seven-point scale |
| Comparator | Same antiemetic regimen plus carrier-matched placebo |
| Duplicate-detection key | ginger|Aphios-liquid-extract-olive-oil-capsules|oral-addon|adults-with-prior-chemotherapy-nausea|first-24h-mean-nausea-reduction|6-days-per-cycle |
Gap Measurement · Verdict 3048 · C 50
What the research actually shows
The largest dose-ranging trial, an 84-mg active-compound standardized trial, and systematic reviews from 2019-2025 were compared.
Why this is classified as C (50)
Independent NCI funding is a strength, but the paper-registry primary-outcome conflict requires EX, and missingness and precision limitations yield C with 50 points.
Counterpoint. Recent syntheses show signals for grade-3 acute nausea or acute vomiting, but those are different severity and endpoint contracts.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 576 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 51 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Ryan JL et al. Support Care Cancer. 2012;20:1479-1489. PMID: 21818642. PMCID: PMC3361530. DOI: 10.1007/s00520-011-1236-3. NCT00040742.
checkedCrichton M et al. J Acad Nutr Diet. 2024;124:313-330.e6. PMID: 37699474. DOI: 10.1016/j.jand.2023.09.003.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Ginger for Acute Chemotherapy Nausea—A Large Trial Was Positive, but Later Standardized and Pooled Results Did Not Agree — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/oral-ginger-adjunct-acute-chemotherapy-nausea-severity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.